• Market Capitalisation market-capitalisation-info ₹97,419 Cr
  • Price to Earnings Ratio price-to-earning 28.21
  • 12 Month Earnings monthly-earning ₹3,453 Cr

Cipla Ltd. Share Price

₹1,205.70

As on 01-Dec-2023 IST

up-down-arrow-6.60-0.54%

  • Prev Close info

    1,212.30

  • Day's Openinfo

    1,213.45

  • Today's Highinfo

    1,217.85

  • Today's Lowinfo

    1,203.50

  • Today's Volumeinfo

    10,78,680

  • 52 Week rangeinfo

    ₹852.00 - 1,283.55

Please wait...

Cipla Ltd. Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cipla
12.06 0.48 -4.13 5.80 17.38 17.39 11.91
S&P BSE Sensex
10.91 5.65 4.09 6.94 15.19 13.27 12.49
S&P BSE Healthcare
32.32 11.76 9.26 27.28 14.47 16.29 12.36
As on 01-Dec-2023
2022
2021
2020
2019
2018
2017
2016
Cipla
13.97 14.21 72.29 -8.57 -15.04 6.98 -13.21
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Healthcare
-12.10 20.87 61.45 -3.55 -5.89 0.49 -12.88

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Cipla Ltd. Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Cipla Ltd.

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        News & Analysis of Cipla Ltd.

        Other details of Cipla Ltd.

        Incorporated

        1935

        Chairman

        Y K Hamied

        Managing Director

        Umang Vohra

        Group

        Cipla

        Headquarters

        Mumbai, Maharashtra

        FAQs for Cipla Ltd.

        The total asset value of Cipla Ltd. stood at ₹ 31,377 Cr as on 30-Sep-23

        The share price of Cipla Ltd. is ₹1,205.70 (NSE) and ₹1,206.65 (BSE) as of 01-Dec-2023 IST. Cipla Ltd. has given a return of 17.38% in the last 3 years.

        Cipla Ltd. has a market capitalisation of ₹ 97,419 Cr as on 01-Dec-2023. As per Value Research classification, it is a Large Cap company.

        The P/B ratio of Cipla Ltd. is 3.92 times as on 01-Dec-2023, a 0.2% premium to its peers’ median range of 3.28 times.

        The P/E ratio of Cipla Ltd. is 28.21 times as on 01-Dec-2023, a -0.06% premium to its peers’ median range of 30.01 times.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Cipla Ltd. and enter the required number of quantities and click on buy to purchase the shares of Cipla Ltd..

        Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

        The prominent promoters of Cipla Ltd. are

        Name of promoters Holding percentage

        Yusuf Khwaja Hameid

        18.68%

        Sophie Ahmed

        5.71%

        Mustafa Khwaja Hamied

        3.46%
        Click here to see the full list

        The chairman of the company is Y K Hamied, and the managing director is Umang Vohra.

        The promoters of Cipla Ltd. have pledged 0% of the total equity as on Sep-23.

        Some of the close peers are:

        Company Market Cap(₹ Cr)
        2,95,418
        1,00,675
        95,867
        72,810
        Cipla Ltd. Ratios
        Return on equity(%)
        14.85
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0.7

        Yes, TTM profit after tax of Cipla Ltd. was ₹3,453 Cr.

        Edit peer-selector-edit
        Please wait...
        Please wait...
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information ₹97,418.94 Cr
        • Revenue (TTM)revenue-information ₹24,556.43 Cr
        • Earnings (TTM) earning-information ₹3,453.22 Cr
        • Cash date-information ₹4,890.69 Cr
        • Total Debt info ₹520.36 Cr
        • Promoters' ownership promoters_ownership 33.47%
        • Liquidity liquidity High
        • 52 Week range week-range ₹852.00 - 1,283.55
        • Face value face-value ₹2.00
        • Shares outstanding share-outstanding 80,73,50,398
        • 10 Years Aggregate:

          CFO: ₹23,400.41 Cr

          EBITDA: ₹32,105.61 Cr

          Net Profit: ₹17,380.93 Cr

        About The Company

        • Incorporated 1935
        • Chairman Y K Hamied
        • Managing Director Umang Vohra
        • Group Cipla
        • Listing key-listing BSE: 500087, NSE: CIPLA
        • Country India
        • Headquarters headquarters Mumbai, Maharashtra
        • Website website www.cipla.com
        • Business

          Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also...  offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.